We have analyzed the profiles of 23 of Plasmodium falciparum strains for their in vitro chemosusceptibilities to piperaquine (PPQ), dihydroartemisinin (DHA), chloroquine, monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine, and doxycycline (DOX) in association with polymorphisms in genes involved in quinoline resistance (Plasmodium falciparum crt [pfcrt], pfmdr1, pfmrp, and pfnhe). The 50% inhibitory concentrations (IC 50 s) for PPQ ranged from 29 to 98 nM (geometric mean ‫؍‬ 57.8 nM, 95% confidence interval [CI] ‫؍‬ 51 to 65) and from 0.4 to 5.8 nM for DHA (geometric mean ‫؍‬ 1.8 nM, 95% CI ‫؍‬ 1.4 to 2.3). We found a significant positive correlation between the responses to PPQ and DHA (r 2 ‫؍‬ 0.17; P ‫؍‬ 0.0495) and between the responses to PPQ and DOX (r 2 ‫؍‬ 0.41; P ‫؍‬ 0.001). We did not find a significant association between the PPQ IC 50 (0.0525 < P < 0.9247) or the DHA IC 50 (0.0138 < P < 0.9018) and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 genes. There was an absence of cross-resistance with quinolines, and the IC 50 s for PPQ and DHA were found to be unrelated to mutations in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 transport protein genes, which are involved in quinoline antimalarial drug resistance. These results confirm the interest in and the efficacy of the combination of PPQ and DHA for areas in which parasites are resistant to chloroquine or other quinolines.
Over the past 20 years, many strains of Plasmodium falciparum have become resistant to chloroquine (CQ) and other antimalarial drugs (32) . This development has prompted the search for an effective alternative antimalarial drug with minimal side effects. One strategy for reducing the prevalence of malaria is the combinatorial use of drugs, which is thought to protect against the development of resistance to each drug and to reduce the overall rate of transmission of malaria (52) . Since 2001, more than 60 countries have officially adopted artemisinin-based combination therapies (ACTs) for the treatment of falciparum malaria (40) , and the official first-line antimalarial treatment in Africa is now ACT (18) . The artemisinin derivatives cause rapid and effective reductions in the parasite biomass and the level of gametocyte carriage, while the partner drug, which has a longer duration of action, achieves effective clinical and parasitological cure. Several different ACTs have been evaluated, including artesunate-sulfadoxine-pyrimethamine (PY) (50) , artesunate-amodiaquine (7), artemether-lumefantrine (LMF) (53) , artesunate-mefloquine (MQ) (2), artesunate-chlorproguanil-dapsone (42) , artesunate-atovaquone (ATV)-proguanil, artesunatepyronaridine (44) , and dihydroartemisinin (DHA)-piperaquine (PPQ) (1, 22, 47) .
However, individual P. falciparum isolates resistant to artemisinin in vitro and the first clinical failures have been described in Cambodia (10, 16, 39, 45) . In addition, prior therapy with an amodiaquine-containing ACT has been found to select for a reduced response to monodesethylamodiaquine (MDAQ), suggesting that amodiaquine-containing regimens may rapidly lose efficacy in Africa (38) . This emergence of parasites resistant to ACTs underlines the fact that novel compounds and combinations must be discovered and developed.
DHA-PPQ is an inexpensive, safe, and highly effective treatment for uncomplicated falciparum and vivax malaria (36, 43) . DHA-PPQ has been shown to offer a longer posttreatment prophylactic effect following therapy than artemether-lumefantrine (27, 53, 54) or artesunate-amodiaquine (23) . The significantly lower risk of recurrent parasitemia after treatment with DHA-PPQ is likely explained by differences in the pharmacokinetics of the nonartemisinin partner drugs. PPQ, a bisquinoline, is estimated to have an elimination half-life of 17 to 33 days (28, 47, 48) , while the elimination half-life of lumefantrine is 4 to 10 days (19) and that of amodiaquine is 1 to 6 h (the half-life of its active metabolite, monodesethylamodiaquine, is 1 to 10 days). Bisquinolines are compounds with two quinoline nuclei bound by a covalent aliphatic or aromatic link.
The first aim of the present work was to assess the in vitro cross-resistance of PPQ with other quinoline drugs, whether they are artemisinin partners or not. The following drugs were tested: CQ, quinine (QN), MQ, MDAQ, LMF, DHA, ATV, PY, and doxycycline (DOX). The second aim was to identify genetic polymorphisms in the Plasmodium falciparum crt (pfcrt) pfcrt, pfmrp, pfmdr1, and pfnhe-1 genes, which are known to be associated with reduced quinoline susceptibility, that could be associated with decreased susceptibility to PPQ with the goal of identifying molecular markers of PPQ resistance for use in resistance surveillance.
MATERIALS AND METHODS

Plasmodium falciparum cultures.
A total of 23 preidentified parasite strains (well-characterized laboratory strains or strains obtained from isolates after growth in culture for an extended period of time) from a large panel of countries (Brazil, Cambodia, Cameroon, Comoros, Djibouti, The Gambia, French Guyana, Honduras, Indochina, Niger, Republic of Congo, Senegal, Sierra Leone, Sudan, Thailand, and Uganda) (24, 25, 41) were maintained in culture in RPMI 1640 (Invitrogen, Paisley, United Kingdom) supplemented with 10% human serum (Abcys S.A., Paris, France) and buffered with 25 mM HEPES and 25 mM NaHCO 3 . Parasites were grown in type A-positive human red blood cells under controlled atmospheric conditions that consisted of 10% O 2 , 5% CO 2 , and 85% N 2 at 37°C with a humidity of 95%. All strains were synchronized twice with sorbitol before use (31) . Clonality was verified using PCR genotyping of polymorphic genetic markers msp1 and msp2 and microsatellite loci (6, 26) . The susceptibility of each strain to antimalarial drugs was assessed in 6 to 21 independent experiments.
Drugs. PPQ was obtained from Rambaxy (India), and DHA was obtained from Shin Poong Pharm Co. (Seoul, South Korea). CQ, QN, PY, and DOX were purchased from Sigma (St. Louis, MO). MDAQ was obtained from the World Health Organization (Geneva, Switzerland). MQ was from Roche (Paris, France), LMF was from Novartis Pharma (Basel, Switzerland), and ATV was from GlaxoSmithKline (Evreux, France). PPQ, QN, MDAQ, MQ, DHA, ATV, and DOX were first dissolved in methanol and then diluted in water to obtain final concentrations ranging from 0.8 to 1000 nM for PPQ, 5 to 3,200 nM for QN, 1.56 to 1,000 nM for MDAQ, 3.2 to 400 nM for MQ, 0.1 to 100 nM for DHA, 0.3 to 100 nM for ATV, and from 0.1 to 502 M for DOX. CQ and PY were resuspended and diluted in water to concentrations ranging from 5 to 3,200 nM for CQ and 50 to 40,000 nM for PY. LMF was resuspended and diluted in ethanol to obtain final concentrations ranging from 0.5 to 310 nM.
In vitro assay. For in vitro isotopic microtests, 200 l/well of a suspension of synchronous parasitized red blood cells (final parasitemia of 0.5% and final hematocrit of 1.5%, after suspension in RPMI 1640 SP823 medium with 0.5 g/liter of p-aminobenzoic acid and 10 g/liter of folate for PY and in RPMI 1640 medium for the other drugs) was distributed in 96-well plates predosed with antimalarial drugs. Parasite growth was assessed by adding 1 Ci of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were then incubated for 48 h under controlled atmospheric conditions. Immediately after incubation, the plates were frozen and then thawed to lyse the erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; PerkinElmer) and were washed using a cell harvester (Filter-Mate cell harvester; Perkin-Elmer). The filter microplates were dried, and 25 l of scintillation cocktail (Microscint O; Perkin-Elmer) was placed in each well. The radioactivity incorporated into the nucleotides by the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).
The drug concentration able to inhibit 50% of parasite growth (IC 50 ) was designated the concentration at which the level of tritiated hypoxanthine incorporation reached 50% of the total level of incorporation by parasites in the drug-free control wells. The IC 50 was determined by nonlinear regression analysis of log-based dose-response curves (Riasmart, Packard, Meriden).
Nucleic acid extraction. Total genomic DNA of each strain was extracted using an EZNA blood DNA kit (Omega Bio-Tek, GA). RNA from each strain was purified using a QIAamp blood minikit (Qiagen, Germany).
pfcrt single nucleotide polymorphisms (SNPs). A 1,250-nucleotide fragment of the pfcrt gene was amplified by RT-PCR using primers F1-sense (5Ј-TAA TTT CTT ACA TAT AAC AAA ATG AAA TTC-3Ј) and F1-antisense (5Ј-TTA TTG TGT AAT AAT TGA ATC GAC-3Ј) and sequenced using primers F2-sense 5Ј-TAG GTG GAG GTT CTT GTC TTG GTA-3Ј) and F2-antisense (5Ј-TCG ACG TTG GTT AAT TCT CCT TC-3Ј), as described previously (17) . Amplifications were performed using an Access reverse transcription-PCR (RT-PCR) system kit (Promega, Madison, WI), according to the manufacturer's instructions. Sequencing was conducted using an ABI Prism BigDye Terminator (version 1.1; Applied Biosystems, CA) cycle sequencing ready reaction kit, according to the manufacturer's instructions.
pfmdr1 SNPs. pfmdr1 (PFE1150w) was amplified by PCR using the following primer pairs: primers 5Ј-AGA GAA AAA AGA TGG TAA CCT CAG-3Ј and 5Ј-ACC ACA AAC ATA AAT TAA CGG-3Ј to amplify codons 86 and 184 and primers 5Ј-CAG GAA GCA TTT TAT AAT ATG CAT-3Ј and 5Ј-CGT TTA ACA TCT TCC AAT GTT GCA-3Ј to amplify codons 1034, 1042, and 1246. The reaction mixture consisted of approximately 200 ng of genomic DNA, 0.5 M forward and reverse primers, buffer (50 mM KCl, 10 mM Tris, pH 8.3), 2.5 mM MgCl 2 , 200 M deoxynucleotide triphosphate (dNTP), and 0.3 U of Taq DNA polymerase (Eurogentec) in a final volume of 50 l. The thermal cycler (T3 Biometra) was programmed as follows: an initial 94°C for 2 min, followed by 40 cycles of 94°C for 30 s, 52°C for 30 s, and 72°C for 1 min. A final 15-min extension step was done at 72°C. The amplified fragments were sequenced as described previously. Sequences were analyzed with the software BioEdit sequence alignment editor (version 7.0.9.0).
pfmrp SNPs. PCR amplification followed by sequencing was used to detect SNPs in pfmrp at positions 191 and 437. The primers used for amplification and sequencing were pfmrp-501F (5Ј-TTT CAA AGT ATT CAG TGG GT-3Ј) and pfmrp-1409R (5Ј-GGC ATA ATA ATT GAT GTA AA-3Ј).
pfnhe-1 microsatellite profiles. A sequence containing the ms4760 microsatellite locus described previously (20) was amplified using primers pfnhe-3802F (5Ј-TTATTAAATGAATATAAAGA-3Ј) and pfnhe-4322R (5Ј-TTTTTTATCA TTACTAAAGA-3Ј). The amplified fragments were sequenced as described previously (20) .
Statistical analysis. Assessment of the cross-resistance of standard antimalarial drugs with PPQ was estimated by use of the coefficient of correlation of Spearman (rho) and the coefficient of determination (r 2 ). The Kruskal-Wallis test or the Mann-Whitney U test was used, when appropriate, to test for associations between the IC 50 and mutations. The differences in the IC 50 s for PPQ were then tested 19 times (i.e., once per locus). The probability of getting a significant result with 19 tests at the level of significance of ␣ equal to 0.05 was 1 Ϫ 0.95 19 (1 Ϫ probability of not getting a significant result with 19 tests). According to the Bonferroni correction, it was concluded that a difference was significant when at least 1 of the 19 comparisons yielded a significance level below 0.05/19, or 0.0026.
RESULTS
Twenty-three P. falciparum strains were tested for their in vitro susceptibilities to PPQ, CQ, QN, MQ, MDAQ, LMF, DHA, ATV, PY, and DOX ( Table 1 ). The mean IC 50 s for PPQ and DHA are presented in Table 1 . The IC 50 s for PPQ ranged from 29 to 98 nM (geometric mean ϭ 57.8 nM, 95% confidence interval [CI] ϭ 51 to 65), and those for DHA ranged from 0.4 to 5.8 nM (geometric mean ϭ 1.8 nM, 95% CI ϭ 1.4 to 2.3).
In vitro cross-resistance was measured by pairwise correlation of the IC 50 s of all 23 strains (Table 2) . A significant positive correlation was found between the responses to PPQ and DHA (r 2 ϭ 0.17; P ϭ 0.0495) and between the responses to PPQ and DOX (r 2 ϭ 0.41; P ϭ 0.001). These coefficients of determination were lower than those for CQ and MDAQ (r 2 ϭ 0.84; P Ͻ 0.0001), CQ and QN (r 2 ϭ 0.78; P Ͻ 0.0001), and MDAQ and QN (r 2 ϭ 0.72; P Ͻ 0.0001). No significant correlation between the PPQ IC 50 and the responses to the other antimalarial drugs was found.
The following mutations were identified in at least one strain: M74I, N75E, K76T, A220S, Q271(E/V), N326S, I356T, and I371R in pfcrt; H191Y and S437A in pfmrp; and N86Y, Y184F, S1034C, N1042D, and D1246Y in pfmdr1 (Table 3) . Eight different ms4760 microsatellite profiles of pfnhe-1 were observed. The number of DNNND and DDNHNDNHNN repeats in ms4760 ranged from 1 to 4 and 1 to 3, respectively.
We did not find a significant association between the PPQ IC 50 (0.0525 Ͻ P Ͻ 0.9247) or the DHA IC 50 (0.0138 Ͻ P Ͻ 0.9018) and polymorphisms in the pfcrt, pfmdr1, pfmrp, or pfnhe-1 gene. However, significant associations between the responses to CQ, MDAQ, QN, and MQ and polymorphisms in pfcrt, as well as between the responses to MDAQ and QN and polymorphisms in pfmrp, were found (Table 4 ). There was no significant association between the ms4760 profile, the DNNND repeat number, and the responses to QN, CQ, MDAQ, or MQ (P Ͻ 0.05 but Ͼ 0.0026). In addition, polymorphisms in pfmdr1 (codons 1034 and 1042) were not signif- 
DISCUSSION
The continued spread of P. falciparum resistance to drug monotherapies has forced a shift toward the use of ACTs. Nevertheless, resistance to at least one component of some ACTs currently in clinical use has been documented, and it is feared that ACTs will gradually lose their clinical efficacy due to their widespread use. Individual P. falciparum isolates resistant to artemisinin in vitro and the first clinical failures or at least longer parasite clearance times have been described in Cambodia (10, 16, 39, 45) . In addition, prior therapy with an amodiaquine-containing ACT has been found to select for a reduced response to monodesethylamodiaquine, suggesting that amodiaquine-containing regimens may rapidly lose efficacy in Africa (38) . In vitro drug interactions between PPQ and artemisinin derivatives have been reported to be indifferent or antagonistic (14, 21, 34, 46) . However, while a combination of PPQ and DHA has undergone successful clinical evaluation in Africa and Asia (1, 5, 22, 47) , the clinical failures of PPQ have been reported in the areas of China where it has been deployed as monotherapy (15) . The goal of the present study was to investigate the susceptibilities of several strains of P. falciparum to PPQ, DHA, and the commonly used antimalarial drugs, as well as to identify cross-susceptibilities between these drugs and the molecular determinants of susceptibility.
Twenty-three P. falciparum strains were tested for their in vitro susceptibilities to PPQ, CQ, QN, MQ, MDAQ, LMF, DHA, ATV, PY, and DOX. The IC 50 s for PPQ ranged from 29 to 98 nM (geometric mean ϭ 57.8 nM, 95% CI ϭ 51 to 65). These data are consistent with the results of previous studies on P. falciparum strains (21) and isolates from Kenya (geometric mean ϭ 50 nM), Cameroon (geometric mean ϭ 39 nM), and the Thai-Burmese border (geometric mean ϭ 49 nM) (3, 4, 35) . In addition, we found that PPQ was highly active against CQ-and PY-resistant strains and against parasites with reduced susceptibility to QN, MDAQ, or MQ.
It was encouraging that we did not find a correlation between responses to PPQ and to the other quinoline drugs (i.e., CQ, QN, MDAQ, LMF, and MQ). These results suggest that no cross-resistance exists between PPQ and CQ or the other quinoline antimalarial drugs. These data are consistent with those from previous studies, which showed weak coefficients of determination (between 0.066 and 0.14) for correlations between PPQ and CQ (3, 35) . The potency of PPQ against CQ-, QN-, MDAQ-, and MQ-resistant P. falciparum strains and the absence of cross-resistance suggest that PPQ and CQ have different modes of action or mechanisms of resistance. Muangnoicharoen et al., who demonstrated cross-resistance between PPQ and CQ in standard lines of P. falciparum, suggested that the pfcrt haplotypes CVIET and SVMNT, which lead to CQ resistance, are positively associated with reduced susceptibility to PPQ (34) . Based on the simple fact that PfCRT-dependent CQ resistance is present at high levels almost everywhere where malaria is endemic, they concluded that PPQ resistance will rapidly develop when the drug is extensively used. This cross-resistance between PPQ and CQ may explain the relatively high rate of treatment failure for PPQ and DHA com- VOL. 54, 2010 PIPERAQUINE AND QUINOLINE RESISTANCE GENES 3541 binations in some areas (29) . However, our molecular data, consistent with the results of a previous study (35) , suggest that PPQ susceptibility is not associated with polymorphism in pfcrt. This result is consistent with the finding that the ability of mutant PfCRT to confer CQ resistance is highly specific to CQ (30) . Resistance was rapidly lost following subtle structural modifications of the basic diethylamino side chain that is linked to the 4-aminoquinoline ring. Cross-resistance was clearly evident with analogs that varied by only a single CH 2 group and was absent when two CH 2 groups were removed or six were added (30) . In addition, Dictyostelium discoideum transformants expressing the CQ resistance phenotype PfCRT were not able to expel PPQ (37) . The absence of an interaction between PPQ and PfCRT suggests that resistance reversal agents would not modify the phenotypic response to PPQ. In particular, at concentrations that completely reverse CQ resistance, verapamil did not affect the relative PPQ response in D. discoideum transformants expressing PfCRT (37) . In contrast to QN, quinidine, MQ, amodiaquine, or primaquine, neither PPQ nor artemisinin inhibits the transport of CQ via PfCRT (33) . The mode of action of PPQ seems to differ from those of other quinolines. In addition, in the present study, we found that IC 50 s for PPQ were unrelated to mutations occurring in the pfcrt, pfmdr1, pfmrp, or pfnhe-1 transport protein genes, which are involved in quinoline antimalarial drug resistance. Crowe et al. showed that the human P glycoprotein Pgp, the homologue of Pgh1 or PfMDR1 (encoded by pfmdr1) in P. falciparum, was not a transporter for PPQ in Caco-2 cells (11). The potency of PPQ against CQ-, QN-, MDAQ-, and MQresistant P. falciparum strains, the absence of cross-resistance with quinolines, and the absence of an association with polymorphisms in quinoline resistance genes suggest that the two types of drug have different modes of action or mechanisms of resistance.
We found a significant positive correlation between the responses to PPQ and DHA and between the responses to PPQ and DOX. Nevertheless, these coefficients of determination were lower than those for CQ and MDAQ, CQ and QN, and MDAQ and QN. A positive correlation between the IC 50 s of two antimalarial drugs may suggest in vitro cross-resistance or at least common mechanisms of action; however, the relationship between in vitro and in vivo resistance depends on the level of resistance and the coefficients of correlation and determination. To suggest that two compounds have the same mechanism of action or resistance (which could induce cross-resistance), the coefficient of determination must be high, such as the one for CQ and MDAQ (r 2 ϭ 0.84). A coefficient of determination of 0.17 means that 17% of the variation in the response to PPQ is explained by a variation in the response to DHA. These results could suggest different modes of drug uptake and/or mechanisms of action of PPQ and DHA. The IC 50 s for DHA were also found to be unrelated to mutations occurring in the transport protein genes involved in quinoline antimalarial drug resistance.
A significant positive correlation was also shown between the responses to PPQ and DOX (rho ϭ 0.64; P ϭ 0.001), with the coefficient of determination being 0.41, suggesting that 41% of the variation in the response to PPQ is explained by a variation in the response to DOX. The mechanism of action of PPQ is not clear, but there is strong evidence that PPQ, like CQ, interacts with heme in the digestive vacuole of the parasite and prevents the conversion of toxic hematin to ␤-hematin (51) . While the mechanism of action is not clearly defined for P. falciparum, two recent studies confirm the specific action of cyclines on the apicoplast of P. falciparum (12, 13) . In vitro susceptibility to DOX has been found to be associated with polymorphism and the copy number of pftetQ, which encodes an analog of a member of the translation elongation factor GTPase family. In addition, DOX susceptibility has been associated with the copy number of pfmdt, which encodes a putative metabolic drug transporter of the plasma membrane with sequence similarity to the tetracycline resistance protein TetA, an efflux pump involved in bacterial resistance to cyclines (9) . It would be interesting to assess the association between in vitro responses to PPQ and these polymorphisms or gene copy number modifications. However, the DOX IC 50 s of the 23 tested strains ranged from 4.6 to 13.4 M, and all strains were susceptible to DOX (8) .
In the present study, the excellent antimalarial activities of ACT components PPQ and DHA were confirmed and were even found against parasites resistant to CQ or PY and with reduced susceptibility to QN, MDAQ, or MQ. The absence of cross-resistance with quinolines and the fact that the IC 50 s for PPQ or DHA were found to be unrelated to mutations occurring in the transport protein genes involved in quinoline antimalarial drug resistance confirm the interest in and the efficacy of the combination of PPQ and DHA for areas in which parasites are resistant to CQ (5, 49, 55) . However, this is a preliminary report. The findings for 23 strains may not be sufficient to make definite conclusions. The validity of the conclusions should be further supported by analyzing more isolates.
